Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00291_DB01097_nanopub.RAcPcRdxZylyWCPW009nj_LHbispdC0Y4mbGizFCzjgbM#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00291_DB01097 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00291_DB01097 label "DDI between Chlorambucil and Leflunomide - Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. [drugbank_resource:DB00291_DB01097]" assertion.
- drugbank_resource:DB00291_DB01097 identifier "drugbank_resource:DB00291_DB01097" assertion.
- drugbank_resource:DB00291_DB01097 title "DDI between Chlorambucil and Leflunomide - Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy." assertion.
- drugbank:DB00291 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00291_DB01097 assertion.
- drugbank:DB01097 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00291_DB01097 assertion.